← Product Code [HQF](/submissions/OP/subpart-e%E2%80%94surgical-devices/HQF) · K100253 # VISUMAX LASER KERATOME (K100253) _Carl Zeiss Meditec, AG · HQF · Jul 8, 2010 · Ophthalmic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/HQF/K100253 ## Device Facts - **Applicant:** Carl Zeiss Meditec, AG - **Product Code:** [HQF](/submissions/OP/subpart-e%E2%80%94surgical-devices/HQF.md) - **Decision Date:** Jul 8, 2010 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 886.4390 - **Device Class:** Class 2 - **Review Panel:** Ophthalmic - **Attributes:** Therapeutic, 3rd-Party Reviewed ## Intended Use The VisuMax Laser Keratome is indicated for the following: - In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea; - In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea; - In the creation of a lamellar cut/resection of the cornea for lamellar keratoplasty: - In the creation of a cut/incision for penetrating keratoplasty and corneal harvesting. ## Device Story Ophthalmic surgical femtosecond laser; creates corneal incisions/flaps via micro-photodisruptions. Input: tissue targeted by tightly focused ultrashort laser pulses; delivered through disposable applanation lens under low vacuum. Operation: 500 kHz pulse repetition rate; increased from 200 kHz; reduced peak power/therapy pulse energy. Used in clinical settings by ophthalmologists. Features: trackball, touchscreen GUI, improved patient support ergonomics, additional slit projector, IR light source for surgical field illumination. Output: precise lamellar/penetrating corneal cuts. Benefit: enables accurate, reproducible corneal surgery; facilitates lamellar and penetrating keratoplasty. ## Clinical Evidence Bench testing only. Ex-vivo porcine eye studies confirmed accuracy and reproducibility of lamellar keratoplasty incisions across various depths/diameters, showing equivalence to predicate. Ex-vivo human globe study confirmed comparable performance for full penetrating keratoplasty between subject and predicate devices. ## Technological Characteristics Femtosecond laser; 500 kHz pulse repetition rate; disposable applanation lens; low vacuum fixation. Includes trackball, touchscreen, IR light source, and slit projector. Hardware/software modified for increased pulse rate and improved ergonomics. Energy delivery parameters adjusted (reduced peak power/therapy pulse energy). ## Regulatory Identification An ophthalmic laser is an AC-powered device intended to coagulate or cut tissue of the eye, orbit, or surrounding skin by a laser beam. ## Predicate Devices - HORUS Laser Keratome ([K062314](/device/K062314.md)) - IntraLase FS Laser ([K041893](/device/K041893.md)) ## Reference Devices - IntraLase FS Laser ([K993153](/device/K993153.md)) - IntraLase FS Laser ([K001211](/device/K001211.md)) - IntraLase FS Laser ([K002890](/device/K002890.md)) - IntraLase FS Laser ([K013941](/device/K013941.md)) - IntraLase FS Laser ([K031960](/device/K031960.md)) - IntraLase FS Laser ([K060372](/device/K060372.md)) - IntraLase FS Laser ([K063682](/device/K063682.md)) - IntraLase FS Laser ([K073404](/device/K073404.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 2 है ? # 510(K) SUMMARY . # JUL - 8 2010 This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92(a). ## SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED | a. | Applicant: | Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52
7740 Jena
Germany | |----|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | b. | Contact Person: | Judy Brimacombe
Carl Zeiss Meditec, Inc.
5160 Hacienda Drive
Dublin, CA 94568
USA
j.brimacombe@meditec.zeiss.com
Tel: (925) 557-4616
Fax: (925) 557-4259 | | c. | Date Prepared: | April 28, 2010 | #### NAME OF DEVICE, INCLUDING TRADE NAME AND CLASSIFICATION NAME | a. | Trade/Proprietary Name: | VisuMax Laser Keratome | |----|-------------------------|-------------------------------------------------------------| | b. | Common/Usual Name: | VisuMax Laser Keratome | | c. | Classification Name: | Laser Instrument, Surgical, Powered
Keratome, AC-powered | | d. | Classification Code(s): | 21 CFR 886.4390; 79 HFQ
21 CFR 886.4310; 79 HNO | #### PREDICATE DEVICES FOR THE VISUMAX LASER KERATOME | PREDICATE DEVICE | MANUFACTURER | 510(k) CLEARANCE NUMBER | CLEARANCE DATE | |----------------------|-----------------------|-------------------------|-------------------| | HORUS Laser Keratome | Carl Zeiss Meditec | K062314 | December 22, 2006 | | IntraLase FS Laser | Abbott Medical Optics | K041893 | July 29, 2005 | {1}------------------------------------------------ #### DEVICE DESCRIPTION The VisuMax Laser Keratome is an ophthalmic surgical femtosecond laser intended for use in patients requiring corneal incisions. The cutting action of the VisuMax Laser Keratome is achieved through precise individual micro-photodisruptions of tissue, created by tightly focused ultrashort pulses which are delivered through a disposable applanation lens while fixating the eye under very low vacuum. #### STATEMENT OF INTENDED USE The VisuMax Laser Keratome is indicated for the following: - . In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea; - In patients undergoing surgery or other treatment requiring initial lamellar . resection of the cornea; - In the creation of a lamellar cut/resection of the cornea for lamellar . keratoplasty: - In the creation of a cut/incision for penetrating keratoplasty and corneal . harvesting. #### TECHNOLOGICAL CHARACTERISTICS COMPARISON The VisuMax Laser Keratome laser is substantially equivalent to the HORUS Laser Keratome also by Carl Zeiss Meditec (K062314), as well as the IntraLase FS Laser (K041893) by Abbott Medical Optics. The VisuMax Laser Keratome has the same operating characteristics as the predicate devices, the HORUS (5062314), and the IntraLase FS Lasers (K993153, K001211, K002890. K013941. K031960. K041893. K060372. K063682. and K073404). Therefore, the VisuMax Laser Keratome is substantially equivalent to these legally marketed predicate devices. ## SUMMARY OR PROPOSED MODIFICATIONS INCLUDED IN THIS 510(K) PREMARKET NOTIFICATION The subject of this traditional premarket notification 510(k) is the expansion of the indications for use of the predicate device (HORUS Laser Keratome) to include lamellar keratoplasty and penetrating keratoplasty, consistent with the indication for use of the predicate device for other commercially available femtosecond lasers. The indications for use for the VisuMax Laser Keratome would be the same as those for the predicate device (the IntraLase FS Laser). {2}------------------------------------------------ Additionally, modifications have been introduced to the device hardware and software specifications in order to allow for the addition of the lamellar and penetrating keratoplasty capability and to enhance the laser's usability in the clinic setting. These modifications include: - An increase in pulse repetition rate from 200 kHz to 500 kHz to allow the . femtosecond resections and/or incisions to be performed with acceptable procedure times - An increase in the maximum average laser power as a result of the higher pulse . repetition rate, however the total laser energy delivered to the eye is unchanged - Reduction of the maximum laser pulse peak power and the therapy pulse energy . - The addition of a trackball and touch screen to the GUI . - Improved ergonomics of the Patient Supporting System and to the laser housing . to facilitate the ease of use - An additional slit projector to facilitate better patient handling . - An additional IR light source to improve illumination of the surgical field . ### BRIEF SUMMARY OF PRE-CLINICAL AND CLINICAL PERFORMANCE TESTING The VisuMax Laser keratome has been designed and tested to applicable safety standards. The performance data supporting safety and substantial equivalence of the VisuMax Laser Keratome to the predicate devices are summarized as follows: - Ex-vivo porcine eye studies demonstrate the accuracy and reproducibility of the . VisuMax Laser Keratome for lamellar keratoplasty incisions and that the level of precision is maintained over a wide range of incision diameters and depths. The results further demonstrate that the proposed device performed equivalently to the predicate device. - Ex-vivo study in human globes shows that the quality of the full penetrating . keratoplasy performance of the VisuMax Laser Keratome and the predicate device are comparable. #### CONCLUSION The VisuMax Laser Keratome is substantially equivalent to the predicate devices. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features the department's name in a circular arrangement around a stylized symbol. The symbol is a representation of a human figure embracing a bird, which is meant to symbolize the department's mission of protecting and promoting the health and well-being of Americans. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Carl Zeiss Meditec AG c/o Mr. Ned Devine Senior Staff Engineer Underwriters Laboratories, Inc. 333 Pfinsten Road Northbrook, IL 60062 Re: K100253 Trade/Device Name: VisuMax Laser Keratome Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic Laser Regulatory Class: II Product Codes: HQF, HNO Dated: June 22, 2010 Received: June 23, 2010 Dear Mr. Devine: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. JUL -- 8 2010 If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {4}------------------------------------------------ forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours. Sincerely yours, Kesia Alexander Malvina B. Eydelman, M.D. Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ K100293 510(k) Number (if known): Device Name(s): VisuMax Laser Keratome Indications for Use: The VisuMax Laser Keratome is indicated for the following: - · In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea; - · In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea; - · In the creation of a lamellar cut/resection of the cornea for lamellar keratoplasty; - · In the creation of a cut/incision for penetrating keratoplasty and corneal harvesting. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Page l of e Evaluation (ODE) (Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices 510(k) Number K100253 510(K) PREMARKET NOTIFICATION CARL ZEISS MEDITEC VISUMAX LASER KERATOME Volume 1, Page20 --- **Source:** [https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/HQF/K100253](https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/HQF/K100253) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com